Connor, Clark & Lunn Investment Management (CC&L)
ALBO

Connor, Clark & Lunn Investment Management (CC&L)’s Albireo Pharma Inc ALBO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,724
Closed -$210K – 1517
2022
Q4 		$210K Sell
9,724
-337
-3% -$7.12K ﹤0.01% 1047
2022
Q3 		$195K Buy
+10,061
New +$208K ﹤0.01% 996
2022
Q2 		– Sell
-18,197
Closed -$543K – 1248
2022
Q1 		$543K Buy
18,197
+1,440
+9% +$42.2K ﹤0.01% 771
2021
Q4 		$390K Buy
+16,757
New +$446K ﹤0.01% 847

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALBO Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 9,724 shares — an estimated $210K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALBO in Q4 2021 and held it in 4 quarters. The position peaked at $543K in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 9,724 Albireo Pharma Inc shares in Q1 2023, an estimated $210K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Albireo Pharma Inc in Q4 2021 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Albireo Pharma Inc position peaked at $543K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.